Cancer & AMR Consortium
Supporters
Information
Antimicrobial resistance (AMR) accounts for nearly
1.3 million deaths globally
and is one of the worst threats facing humanity. One group that is significantly at risk is the cancer community. AMR undermines key advances in cancer care by adversely affecting cancer treatment outcomes and threatening the survival of people living with cancer. As many as 1 in 5 cancer patients undergoing treatment are hospitalized due to infection, and antibiotics are the main line of defense. While such a threat is evident, there is a dearth of data that quantifies this link. Further generation of data would highlight the growing threat and support the cancer community in their efforts of improving outcomes and reducing risk of AMR for cancer patients, globally. The Cancer & AMR Consortium is a partnership among the AMR Action Fund, BD, and UICC quantifying the impact of antimicrobial resistance on cancer patients, and sounding the alarm that infections are undermining the advancements that have been made in oncology. To learn more, visit our webpage.
